We use both large and small animal models in our pre-clinical evaluation of gene transfer agents (GTAs) for cystic fibrosis (CF) gene therapy. Here, we report the use of a large animal model to assess three non-viral GTAs: 25 kDa-branched polyethyleneimine (PEI), the cationic liposome (GL67A) and compacted DNA nanoparticle formulated with polyethylene glycol-substituted lysine 30-mer. GTAs complexed with plasmids expressing human cystic fibrosis transmembrane conductance regulator (CFTR) complementary DNA were administered to the sheep lung (n¼8 per group) by aerosol. All GTAs gave evidence of gene transfer and expression 1 day after treatment. Vector-derived mRNA was expressed in lung tissues, including epithelial cell-enriched bronchial brushing samples, with median group values reaching 1-10% of endogenous CFTR mRNA levels. GL67A gave the highest levels of expression. Human CFTR protein was detected in small airway epithelial cells in some animals treated with GL67A (two out of eight) and PEI (one out of eight). Bronchoalveolar lavage neutrophilia, lung histology and elevated serum haptoglobin levels indicated that gene delivery was associated with mild local and systemic inflammation. Our conclusion was that GL67A was the best non-viral GTA currently available for aerosol delivery to the sheep lung, led to the selection of GL67A as our lead GTA for clinical trials in CF patients.
INTRODUCTION
Proof-of-principle for gene transfer has been demonstrated in a number of clinical trials of gene therapy for cystic fibrosis (CF). 1 The level of gene transfer needed to achieve clinical improvement is unclear from these studies, which use molecular markers as outcome measures. The aim of the UK Cystic Fibrosis Gene Therapy Consortium is to take the optimal currently available non-viral formulation into a multi-dose trial assessing, for the first time, clinical end points. In preparation for this, we wished to identify one or more non-viral gene transfer agents (GTAs) with a safety and efficacy profile suitable for use in future clinical trials. The focus on non-viral GTAs is based on current limitations of most viral GTAs, which show loss of efficacy on repeat administration.
Animal models are essential for pre-clinical evaluation of prospective GTAs because in vitro studies are often poorly predictive of in vivo efficacy and fail to model the influence of an intact immune and inflammatory response. Studies in cystic fibrosis transmembrane conductance regulator (Cftr) mutant mice are thought to be useful for testing whether a gene therapy vector can rescue the defects associated with lack of fully functional CFTR in the airway epithelium, such as loss of cyclic adenosine monophosphate-dependent chloride channel activity and/or regulation of epithelial sodium absorption via the sodium channel EnaC. [2] [3] [4] However, studies in the mouse alone are likely insufficient to predict clinical efficiency in CF patients because there are significant differences in disease pathology and airway physiology between mouse and human. Although large animal CF models continue to be developed [5] [6] [7] these are not yet widely available; thus, we have successfully used wild-type sheep to evaluate the safety and efficacy of lung-directed gene therapy in a clinically relevant way. [8] [9] [10] Our choice of species is based on anatomical and functional similarities to human lungs and the observation that similar mechanisms are initiated in response to lung inflammation that follow a familiar pattern of repair and regeneration. Indeed, the sheep model is proving valuable for assessing gene delivery and efficacy, the localisation of transgene expression and the safety of the gene transfer protocol, all crucial end point measurements in human trials. Practicalities relating to animal numbers and costs prevent the use of the ovine model for high throughput screening, therefore we adopted a combined strategy for testing potential GTAs in vivo. GTAs that show promise in initial testing in the nasal epithelium of wild-type mice and that satisfy a set of criteria relating to manufacturing, efficacy following aerosolisation and safety, are tested in the CF mouse nose 11 and subsequently evaluated by aerosol delivery to the ovine lung.
The key role of the sheep studies is to assess whether GTAs, with proven efficacy in the nasal epithelium of wild-type mice, can be delivered to the small airways of a species with similar lung size and anatomy to man using a clinically relevant delivery system. Three GTAs that fulfilled the criteria for selection were cationic lipid 67 (GL67A), compacted DNA nanoparticles (NP) and 25 kDa-branched polyethyleneimine (PEI). In vivo gene transfer following aerosol delivery to the lung has been demonstrated previously with GL67A in both rodents and humans [12] [13] [14] and with PEI in rodents and sheep. 9, 10, 15, 16 Evidence for in vivo gene transfer following administration of NP to the lungs of mice 17, 18 and to CF patients has been reported 19 and although not delivered by aerosol in these studies, maintenance of the physical properties and biological function of NP collected post-aerosolisation has been described. 20 Many differences in the delivery protocols, the DNA vectors and the model systems have made it difficult to assess if any of these GTAs has a significant advantage over the others.
Here, we directly compare the ability of GL67A, NP and PEI to deliver plasmid expressing human CFTR (hCFTR) complementary DNA to ovine airway epithelium after lung aerosol administration. An additional objective was to investigate local and systemic toxicity. We used plasmid DNA (pDNA) containing the short-acting cytomegalovirus immediate/early promoter so that we could evaluate transgene expression and potential acute inflammatory responses 24 h after GTA delivery. A variety of sampling strategies were used to evaluate vectorderived mRNA expression in different lung tissues, including the preparation of samples enriched for cells in the conducting airways. The levels of both transgene hCFTR mRNA and endogenous ovine CFTR (ovCFTR) mRNA were measured, allowing us to report hCFTR mRNA expression as a relative percentage of ovCFTR RNA. Protein expression was also examined by immunofluorescence.
RESULTS
Aerosol administration time for a fixed 20 ml dose varies with GTA Each of the three GTAs was complexed with the plasmid pCIKCFTR and administered to groups of n¼8 sheep. A further group received pCIKLux complexed with PEI (n¼8) to act as a control group for CFTR protein detection; PEI was chosen for the control group for the pragmatic reasons of availability and cost of material. Aerosol delivery was performed using the nebulisation and ventilation system described previously 8, 9 and was well tolerated in all sheep with no adverse effects apparent beyond those normally associated with general anaesthesia in this species. The nebuliser charge volume was held constant at 20 ml, as a similar volume has been safely delivered to patients within an acceptable administration time, therefore different amounts of pDNA were delivered owing to constraints on GTA formulation. The maximum feasible dose of pDNA in the 20 ml volume was 52.8 mg for GL67A, 40 mg for NP and 8 mg for PEI. The estimated DNA doses aerosolised based on weight in nebuliser pre-and post-delivery and the delivery times are noted in Table 1 . All sheep were euthanised B24 h after treatment and samples from naive animals were prepared as controls in some assays (see below).
All GTAs direct expression of mRNA in sheep lung tissue samples We used TaqMan quantitative reverse transcription PCR to measure levels of vector-derived hCFTR mRNA relative to endogenous ovCFTR mRNA (% hCFTR/ovCFTR) in different lung tissues (Figure 1 ). Segmental tissue samples and bronchial brushings (BBr) were collected to investigate tissue distribution of transgene expression after euthanasia. For each animal, two lung segments were removed and four representative samples taken from each, including individual airways from the upper part of the segment and parenchyma (PU) from the upper (proximal), middle and lower (distal) regions. This generated eight tissue samples per animal. Figure 1a shows the quantitative mRNA expression in all the lung tissue samples analysed with the pFIK-B TaqMan assay. Endogenous ovCFTR was detected in 247 out of 248 (99.6%) tissue samples. Tissue samples from a separate group of naive sheep were negative for vector-derived mRNA with the exception of one outlier sample, most likely due to a sampling or labelling error during quantitative reverse transcription PCR determination. For the three pCIKCFTR groups, NP had the lowest overall median value (0.031), with PEI (12.0) and GL67A (48.7) having much higher levels (Figure 1a ).
PEI and GL67A-treated groups have significantly more vectorderived expression (both presence (Generalised Linear Mixed Effect model (GLME)) and amount (Dwass-Steel-Chritchlow-Fligner (DSCF)) test) than NP (Po0.005), but PEI and GL67A were not different from each other for either presence of vector (GLME P¼0.215) or the amount (DSCF P¼0.070; Figure 1a ). The levels of vector-derived mRNA in 32 out of 64 of the samples from animals in the GL67A group were greater than 50% of the endogenous ovCFTR mRNA and the highest median value for an individual animal in that group was 237% of the endogenous level. Importantly, in sheep treated with GL67A, vector-derived mRNA levels were 41% of endogenous levels in 63 out of 64 samples, although there was some variation between sheep.
GL67A directs highest mRNA expression in airway epithelial-cell enriched samples To reduce the potential contribution of non-airway epithelial cells to the mRNA expression data, we also measured transgene expression in airway epithelial cell-enriched samples. Thus, RNA was prepared from BBr samples collected from eight different lung segments of each animal (see Materials and Methods). The average airway epithelial content of the BBr samples collected at post-mortem examination was 61% (range 48%-71%) and endogenous ovCFTR was detected in 209 out of 224 (93.3%) individual BBr samples. Using the pFIK-B Figure 1b) . Endogenous ovCFTR RNA was detected in all 36 pooled pre-and post-treatment BBr samples. Vector-derived mRNA was observed in seven out of eight available pooled post-treatment BBr samples from the GL67A-treated group ranging from 1.1% V/E to 31.5% V/E (median 1.9%). Expression was only detected in 4/6 available samples from the PEI-treated group (0.4% V/E and three positive but not quantifiable) and 0/7 available samples from the NP-treated group. All pooled pre-treatment samples tested were negative for vectorderived mRNA (data not shown).
Analyses of the individual (non-pooled) post-treatment brushing samples revealed that, as with the tissue samples, there was significantly greater median expression (DSCF Po0.05) and presence (GLME Po0.001) of detectable mRNA observed in BBr in the GL67A compared with the NP group. However, in contrast to the tissue samples, there was also a significantly greater presence (GLME Po0.001) of detectable mRNA observed in BBr from the GL67A group compared with the PEI group (Po0.001). This result was not mirrored for the analysis of median expression (DSCF P¼0.082), partly due to the fact that data were limited to three PEI sheep. However, the seven pooled, post-treatment BBr samples of the GL67A group (median¼1.89% V/E) were significantly higher (MW P¼0.036), than that of the six pooled, post-treatment BBr samples of the PEI group (median¼no detectable V/E, Figure 1b ).
Antibody G449 detects hCFTR protein in small airways of treated sheep We also assessed expression of vector-specific hCFTR protein by immunofluorescence using polyclonal antibody G449 that can detect hCFTR against a background of endogenous ovCFTR on cryosections of sheep lung. 21 In a blinded study, highly positive airway cells were observed in several sheep lung sections and these were quantified using a weighted scoring. Figure 2 shows that highly hCFTR-positive cells were detected in 4 out of 12 sections from GL67A-treated sheep A and 2 out of 12 sections from GL67A-treated sheep E. In addition, 4 out of 12 lung sections from sheep C treated with PEI/pCIKCFTR were also highly positive. Figure 2 also shows that in the majority of other sheep, hCFTR protein expression was not readily distinguishable above endogenous signal and no sheep from the group treated with NP was scored positive. Figure 3 shows immunofluorescence in sheep lung sections after CFTR antibody labelling. Double-labelling studies as described previously 21 were performed using two antibodies, G449 (Figures 3a and d) and MATG1061 (Figures 3b and e) , raised against different CFTR epitopes, to confirm that immunofluorescence in the highly positive cells was due to vector-derived hCFTR protein. One sample from the nanoparticle (NP) treatment group was not determined as neither vectorderived nor endogenous ovCFTR mRNA levels were quantifiable and was omitted from the statistical analysis. GL67A and polyethyleneimine (PEI) vs NP group (Po0.005; both presence Generalised Linear Mixed Effect model (GLME) and amount (Dwass-Steel-Chritchlow-Fligner)). (b) mRNA expression in individual bronchial brushing (BBr) samples as follows: PEI: 18 samples from n¼3 sheep; GL67A: 32 samples from n¼4 sheep; and NP: 33 samples from n¼5 sheep. All pre-treatment (naive) BBr samples were negative. Asterisks represent pooled BBr samples from each sheep as described in Materials and methods. An additional six samples from the PEI group and seven samples from the NP group were not determined as neither vector-derived nor endogenous ovCFTR mRNA was present; these samples were omitted from the statistical analysis. GL67A vs NP (for amount Po0.05, and presence, Po0.001) and GL67 vs PEI (presence Po0.001) groups. 
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Evidence of local toxicity following aerosol delivery of GTAs
We also investigated whether any of the treatments induced an inflammatory response in the lung. Bronchoalveolar lavage (BAL) was carried out in all animals before treatment and B24 h after gene transfer (immediately before euthanasia), to measure changes in total and differential cell counts ( Figure 4 ). No differences were observed in the pre-treatment measurements between any of the groups (data not shown). Aerosol delivery resulted in an apparent increase in total BAL cells from pre-to post-treatment in four of the five groups including the water-treated group (Figure 4a ), but statistical analysis of the preto post-treatment change in individual sheep revealed that only the NP and GL67A groups had significantly increased (Wilcoxon signed rank (WSR) P both o0.021), with the other changes not significant (P all 40.109). Although there were also apparent overall differences between the groups in the amount of change (Kruskal-Wallis (KW) test, P¼0.016), post hoc analysis revealed no significant differences between pairs of groups (DSCF P all 40.083). BAL neutrophil levels also significantly increased from pre-to post-treatment in all groups ( Figure 4b ; WSR P all o0.021). There were overall differences in the amount of change between the groups (KW Po0.001), with the GL67A/pCIKCFTR group being significantly different from the other four groups (DSCF P all o0.037), but there were no other differences in Aerosol delivery to anaesthetised sheep lung is associated with mild to moderate histopathological changes at day 1 post-treatment Histological analysis of lung sections was carried out after euthanasia to identify the degree of inflammation. Samples from two segments, one from each side of the lungs, were collected for histological analysis. Pathology was graded according to severity on a scale of 0-4 with 0 indicating no inflammation and 4 indicating very severe inflammation 8 ( Figure 5 ). The lungs of animals in the NP/pCIKCFTR or PEI/pCIKCFTR-treated groups consistently demonstrated relatively mild (grade 1) focal changes with a low level of acute inflammation of the airways and mild interstitial involvement, indistinguishable from lungs of sheep treated with water in a separate study (data not shown).
In animals treated with GL67A, the changes were still focal in nature but consistently of moderate (grade 2) severity (Po0.005 vs NP and PEI; all groups vs naive, DSCF). The majority of airways in the GL67A-dosed sheep contained neutrophils and extension of the neutrophilia into peri-bronchiolar interstitium was a common feature. Importantly, none of the inflammatory changes in these groups was scored as severe (grade 3) or very severe (grade 4).
GTA administration results in changes to clinical parameters consistent with mild systemic toxicity To investigate whether any of the treatments induced systemic inflammation, we measured total white blood cell (WBC) and neutrophil counts from peripheral blood samples, serum acute phase protein haptoglobin levels and temperature before treatment and immediately before euthanasia. No differences were observed between any of the groups for any of the pre-treatment measurements (KW; WBC P¼0.075, neutrophils P¼0.92, haptoglobin P¼0.48, temperature P¼0.57). Analysis of the total WBC counts showed no apparent overall pattern to the change in levels from pre-to posttreatment (data not shown). In contrast to the levels of neutrophils in BAL fluid (Figure 4b ), changes in blood neutrophils following treatment in any of the groups were much less apparent (Figure 6a ). Although the changes in the water and GL67A groups were significantly different from 0 (WSR Po0.020, other groups P40.107), and overall there were apparent differences in changes between the groups (KW P¼0.031), post hoc pairwise analysis revealed no group differed from another (DSCF P40.064). Analysis of the pre-to post-treatment change in haptoglobin for individual groups (Figure 6b ) revealed that only the change in the GL67A group was significantly different from 0 (P¼0.016, WSR; other groups P40.156), and no overall difference in Evaluation of non-viral GTAs in the ovine lung G McLachlan et al the change in haptoglobin between groups (KW P¼0.262). Finally, when temperature was measured immediately before and 24 h after treatment (Figure 6c ), a significant increase in temperature was observed in the NP-, PEI-and GL67A-treated groups (WSR Po0.03), but not for water (P¼0.48) and PEI/pCIKLux groups (P¼0.052). However, there was no overall difference in the amount of temperature change between the groups (KW P¼0.056).
DISCUSSION
This study aimed to evaluate the potential of three candidate non-viral GTAs in the context of aerosol delivery to a large mammalian lung.
The key objective was to compare the ability of each GTA to deliver plasmid to the airway epithelial cells. An additional important objective was to compare the safety of each GTA, particularly in light of previously reported transient acute toxicity following aerosol delivery of GL67A/pDNA to the lungs of CF patients. 13 We used 'first generation' cytomegalovirus-enhancer/promoter plasmids, rich in CpG motifs, which result in a predictable peak of expression in the sheep lung at day 1, even though expression from the promoter is unlikely to be sustained. 22 Our analysis focussed on a single time point at 24 h post-treatment. For the GL67A group we detected vector-derived transgene mRNA expression in the majority of samples (Figures 1a and b) . It is important to emphasise that both vector-derived hCFTR mRNA and endogenous ovCFTR mRNA were measured, so that the levels of transgene mRNA and wild-type mRNA could be compared. Evidence from the literature suggests that expression of as little as 5% of the normal endogenous CFTR mRNA may provide sufficient clinical benefit to patients to make a significant impact on their quality of life. [23] [24] [25] [26] When we measured mRNA from coarsely chopped lung tissue samples (Figure 1a) , where the epithelial cell content was likely to be considerably o50%, it was encouraging to note that the median values for the GL67A group were near or above the endogenous ovCFTR level. These data also indicate the wide distribution of transgene expression in both sides of the lung, from large conducting airways in the proximal portion of the segment Airway Upper (AWU), to more distal parenchyma (L), which contains many of the target small airways. However, we were unable to identify whether potential target populations of cells had been transfected because the samples analysed contained many different cell types. We have had some success in measuring vector-derived mRNA in small airway epithelial samples collected by laser capture (unpublished data), but such a labour-intensive protocol was not practical for a study of this scale. We therefore used BBr cells collected by cytology brush, a strategy that is applicable to patient samples in clinical trials. We detected robust levels of vector-derived RNA in the BBr samples that had an average epithelial cell content of 61% (Figure 1b) . The quantification of vector-derived mRNA expression in cells of the airway epithelium, as a percentage of endogenous ovCFTR RNA, allowed direct comparison of the three GTAs. Importantly, in the BBr samples, we observed significantly higher vector-derived mRNA levels in the GL67A-treated animals compared with those treated with PEI or NPs, although the mean level achieved, 2.3% of endogenous, was lower than that observed in the tissue samples, possibly reflecting differences in the sampled region. Although BBr samples are enriched for airway epithelial cells, they were collected from airways of B3-5 mm in diameter, which might be considered to be proximal to the presumed disease target cells, whereas the tissue samples would contain the smaller airways in addition to all the other cell types present. The presence of mRNA in the BBr samples indicates that at least a proportion of the overall expression is derived from airway epithelial cells. The higher level of expression from GL67A-treated BBr samples may be a reflection of the higher DNA dose administered to this group, better deposition of this formulation in the larger conducting airways accessible by BBr, or higher gene transfer efficiency. If expression was normalised to DNA dose for each of the formulations then it is likely that GL67 would have no significant advantage over PEI; however, to get equivalent DNA dose with this PEI formulation the volume for delivery would be 132 ml resulting in a delivery time/ 
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volume that could not be translated to the clinic. In effect the dose of PEI formulation is the maximal feasible dose.
The presence of hCFTR mRNA in the majority of crude tissue and BBr samples from GL67A/pCIKCFTR-treated sheep (90 out of 96,) indicated widespread gene delivery and expression. This is encouraging as mRNA detection in the airways has proved difficult in several studies. In one study involving aerosol delivery of a similar dose of GL67A/pDNA to CF patients, no vector-derived mRNA was detected despite evidence for correction of the chloride transport abnormality. 13 The improved detection of mRNA in a second study in which four out of nine BBr samples tested positive may be explained by optimised RNA preparation and assay protocols. 14 A clinical trial with NP administered to the nose of CF patients also reported changes in nasal PD measurements in the absence of detectable vector mRNA. 19 We detected expression of hCFTR protein in cells of the small airways by immunofluorescence (Figures 2 and 3) . Although a previous study of non-viral gene transfer in pigs 27 demonstrated transgene expression in airway epithelial cells of a large mammalian lung, the GTA was delivered by bronchoscopic instillation. Ours is the first report of hCFTR expression in what is perceived to be a relevant target cell population after whole-lung aerosol delivery. In contrast to the mRNA data, we only observed positive anti-CFTR antibody signal in bronchioles from three sheep, two out of eight treated with GL67A and one out of eight treated with PEI. In addition, only one of these sheep, treated with GL67A, showed evidence for hCFTR protein expression in more than one of the lung segments analysed. mRNA levels in these sheep were not apparently higher than sheep with no detectable hCFTR protein, although correlations between these two assays are difficult, as only a very small proportion of the total area of three lung segments was sampled for immunofluorescence. It is possible that in the majority of cells there may be insufficient mRNA to produce enough hCFTR protein for antibody detection, except in a few cells with the highest level of mRNA expression. It is also possible that the synthesis and processing of hCFTR in ovine cells is less efficient than it would be in human epithelial cells. What is clear, however, is that we have an incomplete understanding of the relationship between transgene mRNA and protein expression in this type of study and that a greater level of consistency, in terms of deposition, gene transfer and/or expression, may be required to achieve detectable mRNA and protein in all animals.
We also evaluated GTA safety in our study. The animals exhibited no outward clinical signs, but all three GTAs elicited an acute increase in BAL neutrophil content 24 h post-treatment ( Figure 4 ) and mild to moderate scores in the corresponding histopathological assessment of tissue sections ( Figure 5 ). However, only the changes in the GL67A group reached significance when compared with aerosol delivery of water. The vectors used in this study were all 'first generation' plasmids, which contain high numbers (4300) of CpG motifs, therefore, it is possible that this inflammatory response could be attributed, at least in part, to the presence of non-methylated CpG motifs in the bacterial pDNA, 28 especially, as the GL67A-treated sheep received the largest plasmid dose (52.8 mg in 20 ml). Although the plasmid dose received by the NP group was only B20% less, it has been argued that the markedly reduced inflammation in response to instillation of NP in the mouse lung is due to the pDNA within the NP formulation being masked from the toll-like receptor 9 in the endosome, 18 as a consequence of a nucleolin-mediated route of entry to the cell and into the nucleus. 29 Despite this, a modest BAL neutrophil response has been reported for a 100 mg dose administered to the lungs of Balb/c mice, 18 which could be consistent with the trend towards increased BAL neutrophils observed after lung delivery in the sheep.
Although no inflammatory response was reported following administration of NP to patients, 19 it should be noted that the NP delivery was restricted to the nose of CF patients, an organ that in our hands is not predictive of lung toxicity.
It is unlikely that the presence of CpG motifs in pDNA is the sole reason for the inflammatory response, as we have observed that delivery of GL67A alone to the sheep lung can result in increased BAL neutrophils (unpublished data). This contrasts to the lack of effect of aerosol administration of GL67A alone to the lungs of normal volunteers, 30 revealing a potential difference in the lung biology of sheep and humans, although differences in amounts and regional distribution of material deposited in the lung in the different systems cannot be ruled out.
The increases in haptoglobin and peripheral blood neutrophil counts observed following GL67A delivery in this study are also consistent with clinical aerosol delivery data, 13 where an increase in the acute phase marker C-reactive protein in the active group and a trend towards increased WBC counts in active and placebo groups was observed. This suggests that the sheep lung may be useful in assessing aspects of the inflammatory response to aerosol delivery. As noted previously, the GL67A/pDNA formulation delivered the highest dose of pDNA, and this may further explain why associated markers of toxicity were more conclusively altered in these animals. Additional studies show that these responses are transient and have returned to baseline by day 4 post-treatment (unpublished data). We anticipate that repeated administration of a non-viral GTA will be required in a clinical situation and it is unclear how the observed mild inflammatory response might affect subsequent doses. Since these studies were initiated, we have developed new generations of plasmid vectors with few or no CpG motifs and preliminary findings show that these lead to reduced inflammatory cytokine levels and BAL cell counts in the mouse lung when complexed with GL67A. 31 Monthly administration (9 doses) of GL67A complexed with one of these zero-CpG plasmids with a promoter sequence that is known to extend the duration of expression following aerosol delivery to the lungs of mice 22 is currently being tested in our large animal model. It is possible that the level of gene delivery reported here, coupled with improved duration of expression, may be sufficient to significantly improve the results of clinical outcome assays in long-term trials in patients.
In summary, we have directly compared three candidate non-viral GTAs in the context of aerosol delivery to the sheep lung, where each GTA was capable of hCFTR expression in lung tissue samples. Importantly, GL67A resulted in robust and widespread vector-derived mRNA expression in the lung, including samples enriched for epithelial cells, as well as giving evidence of hCFTR protein expression in small airways in a few animals. However, GL67A delivery was also associated with lung and systemic toxicity. The dosed sheep did not appear systemically ill and the toxicity indicators resolved several days after dosing, but similar acute lung responses have also been observed in CF patients. 13 Consequently, we have modified our CFTR expression plasmids by removing CpG motifs to minimise such acute toxicities, and have improved the duration of hCFTR expression 31 to increase the potential for observing clinical benefit after repeated administration. In conclusion, we have selected cationic liposome GL67A as our lead GTA to go forward into single and multiple-dose clinical trials in CF patients. U47119 ) and contain the human CFTR or Lux complementary DNA sequences under the control of the human cytomegalovirus immediate/early promoter/ enhancer, a hybrid intron, an SV40 polyadenylation sequence and an ampicillin resistance gene. 22, 32 High purity plasmids (o5 endotoxin units per mg DNA) were prepared by Aldevron (Fargo, ND, USA). Plasmid DNA was complexed with cationic lipid GL67A or polyethyeneimine (PEI) as previously described. 9 Compacted DNA NP containing pCIKCFTR condensed with poly-L-lysinepolyethylene glycol were prepared by Copernicus Therapeutics Inc (Cleveland, OH, USA) as described previously 17 and supplied in 20 ml aliquots ready for use.
Animals
All experiments were carried out with approval of appropriate local Ethics Committees and according to Home Office regulations.
Suffolk Cross ewes, 35-60 kg, were treated with anthelminthic before the study began and underwent a preliminary examination involving bronchoscopic visualisation and bronchoalveolar lavage under gaseous anaesthesia 1-3 weeks before treatment to confirm absence of pre-existing pulmonary disease. This preliminary BAL procedure was restricted to the accessory lobe (right apical, RA), which branches from the trachea proximal to the carina. The time between preliminary BAL and delivery was 41 week to minimise the likelihood of any effect on gene transfer that might result from changes to airway surface liquid composition. No samples were collected from this region for mRNA analysis.
Pre-treatment sampling
The following lung segment nomenclature was used: RA, right apical; RI, right intermediate; RC, right cardiac; RVD1, RVD2, right ventral diaphragmatic 1 and 2; RCD, right caudal diaphragmatic; LC, left cardiac (cardiac segment of the apicocardiac lobe); LVD1, LVD2, left ventral diaphragmatic 1 and 2; LCD, left caudal diaphragmatic. Blood samples were collected in heparin tubes and subjected to routine haematological analysis to determine cell counts and haptoglobin levels. BAL samples were collected from segment RA by wedging a bronchoscope into the segment entrance then instilling and recovering 2Â20 ml sterile normal saline. BAL fluid was filtered through gauze to remove mucous and large particulates and stored on ice. Total cell number was determined then cytospins were prepared and stained to count neutrophils.
BBr samples were taken from the entrance to each of the eight lung segments for RNA extraction. A new cytology brush was used for each animal and rinsed in phosphate-buffered saline (PBS) between each brushing. Separate brushings were collected in 1 ml PBS then pelleted and processed for RNA extraction. A pooled sample for each sheep was prepared by combining 200 ml from each of the eight 1Â1 ml BBr samples in 4%PFA/3.7%sucrose and snap-frozen for storage.
GTA delivery procedure
On the day of administration, animal temperatures were recorded and blood samples collected for routine haematology. Aliquots of serum were stored frozen. Animals were anaesthetised, intubated and placed in a whole body respirator as described previously 9 with the exception that anaesthesia was induced with an intravenous injection of 6-8 mg kg À1 propofol (Fresenius propofol, 1%, Fresenius Kabi Ltd, Runcorn, UK) and maintained by continuous intravenous infusion of propofol (1%) via a syringe driver (Precidor, INFORS AG, Basel, Switzerland). An intramuscular injection of glycopyrrolate (Robinul Injection, 0.2 mg ml À1 ), a preoperative antimuscarinic that reduces salivary, tracheobronchial and pharyngeal secretions, and enhances transgene expression following delivery of PEI/pDNA complexes, 9 was administered 30 min before GTA delivery at a dose of 0.02 mg kg À1 body weight.
Treatments were staggered over a period of 4 weeks such that in any week two sheep from each group were treated. Animals received GL67A/pCIKCFTR (n¼8), NP/pCIKCFTR (n¼8) or PEI/pCIKCFTR (n¼8). An additional group received PEI/pCIKLux (n¼8) as a control for immunofluorescence studies. For GL67A/pDNA, nebulisers were charged with 20 ml complex representing 52.8 mg (DNA molarity B8 mM). For NP/pDNA, nebulisers were charged with 20 ml of the formulation representing 40 mg (DNA molarity B6 mM). For PEI/ pDNA, nebulisers were charged with 20 ml complex representing 8 mg pDNA (DNA molarity B1.22 mM). GTA was aerosolised through PARI LC plus jet nebulisers at 29 p.s.i. and delivered to animals using the ventilation system described previously. 9 The mass median aerodynamic diameters of pDNA:PEI and pDNA:GL67 aerosols generated under these conditions are 3.78±0.32 mm (n¼5 replicates) and 5.61 ± 0.14 mm (n¼6 replicates), respectively. 9 A mass median aerodynamic diameter reported for the NP formulation was B2.2 mm with a PARI LC Star; 20 however, this is designed to generate smaller droplets than the LC Plus nebuliser. After treatment, anaesthetic delivery was halted and animals were allowed to recover before being taken to separate accommodation.
Necropsy sampling
At 24 h post-treatment the temperature of the animal was recorded and blood samples collected for serum and haematology. Following euthanasia by lethal injection and exsanguination, the lungs were removed for tissue collection. The pulmonary circulation was flushed out via the pulmonary artery with 2-3 l of PBS before sampling. BAL fluid was collected as for pre-treatment sampling but from segment right caudal diaphragmatic. BBr samples were taken from a second site within each of the eight segments and a pooled sample prepared as described above. Lung slices obtained from segments LVD1 and RVD1 (left and right ventral diaphragmatic) were taken as described previously. 9 Upper (proximal) slices were separated by dissection into individual airways Airway Upper (AWU) and parenchyma upper (PU). Representative parenchyma samples were also obtained from middle (M) and lower (L) slices. Although these samples have been termed 'parenchyma' it should be noted that they will also contain small airways. For RNA extraction, samples were finely chopped and stored in RNALater (Ambion, Warrington, UK). Naive tissue samples were collected from a separate group of untreated animals. Sufficient material was collected for multiple extractions. For histopathological analysis a block of tissue from one of the middle slices was fixed in 10% neutral-buffered formalin, then paraffin-embedded, sectioned and stained. Slides were scored blind on a scale of 0 to 4 and graded according to severity of inflammation as described previously. 8, 9 For CFTR immunofluorescence studies, segments LC, RA and RC were inflated with a mix of 30% sucrose:OCT (2:1) and partially frozen on dry ice. Five transverse slices B1-cm thick were cut distal to proximal from each segment then trimmed into blocks B1 cm 3 . Blocks (labelled 1-5) were mounted on cork tile then stored frozen until needed.
RNA analysis
Samples (100 mg) were taken from the tissue stored in RNALater, added to Lysing Matrix D FastPrep tubes (QBiogene, Carlsbad, CA, USA) with 1 ml RLT buffer (Qiagen, Crawley, UK), then processed in a FastPrep homogenizer (QBiogene) for 40 s at speed 6.0. The upper phase was transferred to a Qiashredder tube (Qiagen) and centrifuged at 13 000 r.p.m. for 2 min. The procedure was then completed according to the RNeasy Mini Kit protocol (Qiagen). RNA was eluted with 50 ml nuclease-free water into a 'No Stick' Ambion microfuge tube (Ambion) and quantified spectrophotometrically. TaqMan analysis was initially performed with the pCI-A and ovCFTR TaqMan assays. First analysis of these crude lung tissue samples collected at postmortem examination suggested levels of vector-derived mRNA above the level of endogenous ovCFTR mRNA in all the treatment groups; however, it became apparent that the TaqMan pCI-A assay was particularly sensitive to residual pDNA present in the samples. Therefore, a more stringent DNA removal protocol and an improved TaqMan assay (pFIK-B) were developed to overcome this issue 33 and were applied to all further samples. Subsequently, a second set of tissue RNA samples were prepared as above from the remaining tissue samples stored in RNALater but with the AllPrep Mini Kit protocol (Qiagen) and treated with Ambion DNA-free kit, to remove residual contaminating DNA, before analysis with the pFIK-B TaqMan assay. For BBr samples, RNA was extracted as above but without the FastPrep homogenisation step and initially analysed with the pCI-A and ovCFTR TaqMan assays. Subsequently, where sufficient RNA remained, samples were treated with Ambion DNA-free kit, to remove residual contaminating DNA, before analysis with the pFIK-B TaqMan assay. As the original RNA yield from these small samples was low, the number of samples available for the latter analysis was limited. These included 18 samples from n¼3 PEI sheep; 32 samples from n¼4 GL67A sheep; 33 samples from n¼5 NP sheep. RNA from pooled BBr samples was isolated using Evaluation of non-viral GTAs in the ovine lung G McLachlan et al the FFPE kit (Qiagen) as these samples had been fixed in PFA/sucrose. RNA samples were further treated using Ambion DNA-free kit before TaqMan analysis with pFIK-B.
Absolute levels of mRNA were quantified by two-step, real-time quantitative TaqMan reverse transcription PCR using the ABI PRISM 7700 Sequence Detection System and Sequence Detector v1.6.3 software (Applied Biosystems, Warrington, UK), using plasmid or endogenous mRNA-specific primers and fluorogenic probes. Sequences of the forward (F), reverse (R), probe (P) and reverse transcriptase (RT) reaction priming (R2) oligonucleotides used for each mRNA target are listed below. Where no R2 oligonucleotide is indicated, the R primer was utilised in RT reactions. The pCI-A assay primer set: F: 5¢-GCTTCTGACACAACAGTCTCGAA-3¢, R: 5¢-GGAGTGGACACCTGCCCA-3¢ and P: 5¢-FAM-TGCCTCACGACCAACTTCTGCAGC-3¢-TAMRA. The pFIK-B assay primer set: F: 5¢-TGAGGCACTGGGCAGGTGT-3¢, R: 5¢-GTCGTATTA AGTACTCTAGCCTTAAGA-3¢, P: 5¢-FAM-CCACTCCCAGTTCAATTACAGC-TAMRA-3¢, R2: 5¢-GCTCGTCGTATTAAGTACTCTAGC-3¢. The endogenous ovCFTR, F: 5¢-GGAAAAGGCCAGCGTCGTC-3¢, R: 5¢-CCAAGCGCTGTCTG TATCCT-3¢, P: 5¢-FAM-CCAAACTTTTTTTCAGCTGGACCAGACCAA-TAM RA-3¢. No-template and no-reverse transcriptase (RT-) controls were included, wherein total RNA or MultiScribe RT and RNase inhibitor were omitted from the RT reaction, respectively. The number of copies of vector-derived and endogenous ovCFTR mRNA were calculated for each sample from standard curves of in vitro transcribed RNA fragments that surrounded the amplified region. 26 The amount of vector-derived mRNA was expressed as a percentage of endogenous ovCFTR mRNA, such that samples that contained equivalent amounts of each mRNA are expressed as 100% vector/endogenous mRNA. Samples with vector-derived mRNA levels that were above those observed with no-template controls, yet below those found for the lowest standard were reported as positive but not quantifiable. Samples with quantifiable endogenous ovCFTR, but vector-derived mRNA levels that were not distinguishable from no-template controls, were reported as no detectable vector. Samples with levels of endogenous ovCFTR that were below the lowest standard and samples where the RT-reaction Ct value was within 3 Ct of the mean RT+ Ct value for either the vector-derived or endogenous ovCFTR assay were reported as 'not determined' .
CFTR Immunofluorescence
Frozen sections (8 mm) of lung were prepared as described previously. 21 For each sheep, a total of 12 sections were cut, 4 each from block 3 from lung segments RA, LC and RC. Dual staining with two different anti-CFTR antibodies was also performed on sections from block 3, with all antibodies diluted in 0.5% (w/v) bovine serum albumin in PBS. The human-specific polyclonal anti-CFTR antibody G449 (gift from Hugo de Jonge and Angus Nairn) and the monoclonal antibody MATG1061 (R&D Systems, Abingdon, UK) were used as described previously. 21 In our hands, MATG1061 recognises both ovine and hCFTR at the normal working dilution of 1:100, but endogenous ovCFTR was not detected at a dilution of 1:250. Secondary antibodies (Molecular Probes Europe BV, Leiden, The Netherlands) were Alexa Fluor 488 (goat anti-rabbbit) and 594 (goat anti-mouse). For detection of hCFTR sections were collected from segments RC, RA, LC (n¼4 each, 12 per sheep). Raised coverslips (Coverwell Incubation Chamber, Melford Laboratories, Chelsworth, UK) were used to preserve the morphology of the lung tissue. The pan-cytokeratin antibody (MAB3412; Millipore Ltd, Watford, UK) was used at a dilution of 1:2000. A negative control without primary antibody was included in every experiment. Fluorescence microscopy and image capture were performed as before 21 The number of bronchioles available to assess on each section varied from 22-46. All sections were analysed in a blinded manner, and positive cells scored in representative cryosections according to brightness of signal and cell morphology as described. 21 Only positive cells localised to airway epithelium were scored. All procedures were performed by two operators, and the weighted scores were compared weekly to minimise variation.
Epithelial cell quantification
Cytospins of epithelial cells were prepared from aliquots of the BBr. Slides were washed with 1Â PBS for 3 min, permeablised with 1% Triton X-100 (Sigma, Gillingham, UK) for 20 min, washed with 1Â PBS for three times 5 min and blocked with 1% bovine serum albumin (Sigma) for 45 min. Slides were then incubated for 1 h at 37 1C with a mouse pan-cytokeratin antibody (MAB3412, Millipore Ltd, UK) diluted 1:50 with 0.5% bovine serum albumin. Control slides received antibody diluent only. Slides were then washed three times with PBS for 10 min and incubated for 45 min at room temperature with an Alexafluor 488-conjugated goat anti-mouse antibody diluted 1:500 with 0.5% bovine serum albumin. After washing for 3Â10 min with PBS, slides were mounted with Vectashield (Vector Laboratories, Peterborough, UK) containing 2 mg ml À1 of DAPI (Sigma), covered with a cover-slip and stored in the dark at 4 1C.
Statistical analysis
Statistical calculations were carried out using the Minitab 14.0 package (Minitab Ltd, Coventry, UK). Non-parametric analyses were performed on the RNA, blood WBC, BAL neutrophil, immunofluorescence and toxicology data, as all values were weighted counts, were expressed as percentages, or were not normally distributed. In general the KW test was used across treatment groups to identify any significant differences. If these were found, the DSCF post hoc multiple comparisons test was performed. For RNA samples, analysis using all data collected based on whether there was quantifiable vector mRNA (yes/no) was performed using generalised linear mixed-effect models with binomial errors (GLME), taking into account that there is non-independence of data with up to eight points per sheep, and for the tissue samples, up to four values per segment within sheep (so segment is nested within sheep). For blood WBCs and BAL neutrophils paired pre-and post-treatment samples were available. The one-sample WSR test was used on all 32 data points or on individual groups to determine the significance of any pre-to post-treatment change, then KW was used to determine whether there were any significant differences in the magnitude of the changes between the treatment groups. Usually only significant differences (Po0.05) are reported.
